Obermatt
See Similar Stocks →

Exelixis

NSQ:EXEL · US30161Q1040
BiotechnologyLarge

360

96
EV / EBIT75
Price / Owner Earnings30
Cash yield96
Price/Sales63
EV / Gross Profit85
Price/Book26
Return on Capital100
Cash Return on Capital96
Return on Equity92
EBIT Margin92
Gross Profitability100
Cash Conversion43
Accruals71
Owner Earnings Margin91
Sales growth51
Profit Growth94
Long-Term EPS Growth49
Owner Earnings Growth63
Reinvestment69
Price momentum44
Debt load43
Refinancing86
Debt Payback100
Liquidity—
Analyst ratings11
Opinion Changes50
Price Target Upside6
Market mood74
Value Creation16/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Exelixis generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeLarge
TypePublic Company
ExchangeNASDAQGS
Founded1994
Employees1,279
Websiteexelixis.com
ISINUS30161Q1040
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)S&P MIDCAP (USA)D.J. US Health Care
Themes
PharmacovigilanceCardiovascularOncologyBiotechnologyHealth CarePharmaceutical

Description

Exelixis, Inc. (Exelixis), an oncology company, innovates next-generation medicines and regimens at the forefront of cancer care. The company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule,…

Analysis

Quality compounder

Exelixis, Inc. is a quality compounder: a well-run business trading at a price that reflects what it is worth. One caution: reported profits have recently run ahead of actual cash, which we track closely.

The price is fair. You pay 15.7× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone. At today's price, the market is assuming roughly 3% yearly growth; analysts expect 11%. The price, in other words, assumes less than the experts do.

The trajectory is moderate and the balance sheet is sturdy. The company scores 16/20 on our value-creation score: strong value creator.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

Similar Stocks

The companies this stock is ranked against.

Compare Exelixis with its peers
Coherus Oncology
NMQ:CHRS
72
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Janux Therapeutics
NMQ:JANX
41
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
IDEAYA Biosciences
NSQ:IDYA
18
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Crescent Biopharma
NAQ:CBIO
19
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Rigel Pharmaceuticals
NSQ:RIGL
66
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Puma Biotechnology
NSQ:PBYI
79
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →